nivolumab plus ipilimumab (n=78) vs. no additional treatment (n=75)
randomized controlled trial
nivolumab plus ipilimumab
nivolumab plus ipilimumab induction followed by nivolumab maintenance monotherapy : Consolidation immunotherapy consisted of four cycles of nivolumab [1 mg/kg, every three weeks (Q3W)] plus ipilimumab (3 mg/kg, Q3W), followed by nivolumab monotherapy (240 mg, Q2W) for up to 12 months.
no treatment added
No Intervention: Observation
Consolidation ipilimumab and nivolumab vs observation
limited stage SCLC (ls-SCLC) - maintenance (M)
Patient recruitment closed prematurely due to slow accrual and the statistical analyses plan was updated to address progression-free survival (PFS) as the only primary endpoint.